Sector Analysis2025-11-11
Healthcare Sector Emerges as Defensive Play Amid Aging Demographics
Healthcare ETFs such as VHT and XLV are gaining attention for delivering stable returns amid market volatility. The long-term growth outlook remains bright, supported by an aging population and a favorable drug development pipeline.
AdminCNBC
The healthcare sector has outperformed the S&P 500 in 2025, earning renewed recognition as a defensive investment destination. VHT has gained 18.2% year-to-date and XLV has risen 16.5%, both surpassing the market average of 14.1%. With Americans aged 65 and older now comprising 17.5% of the total U.S. population and projected to reach 21% by 2030, healthcare demand is structurally increasing. Pharmaceutical earnings are also improving, driven by blockbuster drug launches including GLP-1 obesity treatments and new Alzheimer's therapies. Investors should use a rebalancing calculator to review their healthcare sector allocation and an asset allocation calculator to optimize healthcare exposure within a defensive portfolio.
Healthcare Sector Performance and Characteristics
VHT (Vanguard Health Care ETF) holds 480 healthcare stocks, carries an expense ratio of 0.10%, and offers a dividend yield of 1.30%. Its top holdings include UnitedHealth at 8.5%, Eli Lilly at 7.2%, Johnson & Johnson at 6.8%, Merck at 5.9%, and Thermo Fisher at 5.3%. Sector allocation breaks down as follows: Pharma & Biotech 45%, Medical Devices 25%, Healthcare Services 20%, and Life Science Tools 10%. In terms of 2024 performance, VHT posted a year-to-date return of +18.2%, outperforming the S&P 500's +14.1% by 4.1 percentage points. During the October correction, VHT declined only -2.5% versus the S&P 500's -5.2%, delivering 2.7 percentage points of relative outperformance. Annual volatility stands at 16%, well below the market's 20%, reflecting the sector's inherent stability. XLV (Health Care Select Sector SPDR) holds 64 S&P 500 healthcare stocks, carries an expense ratio of 0.09%, and offers a dividend yield of 1.35%. Its top holdings include UnitedHealth at 10.2%, Johnson & Johnson at 8.5%, Eli Lilly at 7.8%, AbbVie at 6.9%, and Merck at 6.3%. The concentration in large-cap names is higher than VHT. In 2024, XLV returned +16.5% year-to-date and declined -3.0% during the October correction, a slightly weaker defense than VHT. The key distinction versus VHT is the exclusion of small- and mid-cap biotech names, which reduces growth potential but enhances stability. Healthcare sector characteristics include: a defensive nature—medical demand persists even during economic downturns, as demonstrated in the 2022 bear market when VHT fell only -4% against the S&P 500's -18%; an aging mega-trend—the U.S. population aged 65 and older is projected to grow from 58 million in 2025 to 73 million by 2030, implying a structural increase in demand; and a robust drug pipeline—the GLP-1 obesity treatment market is expected to reach $100 billion by 2030, new Alzheimer's drug approvals are opening fresh markets, and the expansion of oncology immunotherapy continues to produce blockbuster drugs.
Earnings Outlook for Key Healthcare Companies
UnitedHealth (UNH) is the leading health insurance company with a market cap of $520 billion and is the largest holding in both VHT and XLV. Q3 2024 results showed revenue of $100.7 billion, up +9% year-over-year, with EPS of $7.15 in line with consensus and an operating margin of 8.2%, reflecting solid stability. For 2025, guidance calls for revenue of $450 billion and EPS of $32. Medicare Advantage enrollment is expected to reach 9 million members, up +8%, while the Optum health IT segment is forecast to sustain double-digit growth. The average analyst price target of $640 implies +12% upside from current levels. Eli Lilly (LLY) is the leader in GLP-1 obesity treatments with a market cap of $850 billion, making it the largest healthcare company by market cap. Key products include Mounjaro (diabetes treatment), which is expected to generate $12 billion in 2024 revenue; Zepbound (obesity treatment), which is on a rapid growth trajectory with $5 billion projected in 2024 revenue; and Donanemab (Alzheimer's therapy), scheduled for launch in 2025 with expected annual revenue of $3 billion. For 2025, the company targets 40% market share in GLP-1, projects total revenue of $45 billion representing +25% growth, and maintains a pipeline of more than 20 drugs to sustain long-term momentum. While the P/E ratio of 55x raises valuation concerns, a PEG ratio of 1.2 relative to growth rates appears reasonable. Merck (MRK) holds the oncology blockbuster Keytruda and has a market cap of $280 billion. Keytruda is expected to generate $28 billion in 2024 revenue, accounting for 45% of Merck's total sales. The patent expires in 2028, but label expansion across more than 20 indications—including lung, gastric, and breast cancer—supports continued growth through 2030 and maintains blockbuster status. In its drug pipeline, the HPV vaccine Gardasil contributes a stable $10 billion annually as a cash cow, while $14 billion in annual R&D investment secures next-generation growth drivers. A dividend yield of 2.8% with approximately 10% annual dividend growth also makes MRK attractive for income-oriented investors.
Healthcare ETF Investment Strategies
The healthcare sector allows investors to pursue both defense and growth simultaneously. By investor profile: conservative investors prioritizing stability may consider XLV 20% + SCHD 30% + AGG 40% + Cash 10%—this builds a defensive base with large-cap healthcare names, enhances stability through dividend stocks and bonds, and calls for quarterly rebalancing using a rebalancing calculator. Balanced investors seeking defense plus growth may consider VHT 25% + SPY 35% + QQQ 20% + AGG 20%—allocating 25% to healthcare as the defensive sleeve while maintaining a balanced mix of 55% equities and 20% bonds, with risk managed via an asset allocation calculator. Aggressive investors prioritizing growth may consider VHT 15% + QQQ 40% + SOXX 15% + TQQQ 5% + AGG 15% + Cash 10%—using healthcare as a 15% defensive position, targeting high returns through an equity-heavy tech-focused allocation, and holding cash to buffer volatility. For sector rotation strategies: during economic expansion, reduce healthcare to 15% while expanding technology and financials to 35%, rotating the portfolio toward growth stocks. During economic slowdown, increase healthcare to 25%, add 15% in consumer staples and utilities, shift the portfolio toward defensive sectors, and raise bond allocation to 30%. During periods of heightened uncertainty, maximize healthcare to 30%, hold 40% in bonds and 15% in cash and gold, and reduce overall equity exposure to below 50% when VIX exceeds 30. Within healthcare, a detailed sub-allocation approach may include: a pharma and biotech tilt—allocate 40% to drug developers such as Eli Lilly and Merck that benefit from regulatory exemptions, while being mindful of higher growth potential alongside greater volatility; adding medical devices—allocate 25% to Medtronic and Boston Scientific to benefit from stable demand and technological innovation; and healthcare services—allocate 35% to UnitedHealth and CVS Health to capture direct aging tailwinds and stable cash flows.
The Aging Mega-Trend and Healthcare Demand
Shifting U.S. demographics underpin the long-term growth of the healthcare sector. The share of Americans aged 65 and older was 16.5% in 2020, rose to 17.5% in 2025, is projected to reach 21.0% by 2030, and is expected to peak at 23.5% by 2040. The Baby Boomer generation—76 million Americans born between 1946 and 1964—will all have crossed age 65 by 2030, pushing Medicare enrollment from 65 million to 85 million and driving a surge in chronic disease management demand. Per-capita healthcare spending for those aged 65 and older averages $20,000 per year, 1.7 times the overall average of $12,000. For those 75 and older the figure rises further to $28,000 per year. Total healthcare spending is expected to expand from 17.5% of GDP to 19.5% by 2030. By key disease category: the diabetes market is projected to grow from $80 billion in 2025 to $120 billion in 2030, with GLP-1 drugs reshaping the landscape; the Alzheimer's market is expected to surge from $8 billion in 2025 to $25 billion in 2030, with new drug approvals opening fresh markets; the oncology market is set to expand from $200 billion in 2025 to $300 billion in 2030, driven by immuno-oncology and targeted therapies; and the cardiovascular disease market stands at a stable $60 billion in 2025, with sustained demand given that heart disease remains the leading cause of death among older Americans. On the policy front, the Inflation Reduction Act introduced Medicare drug price negotiations, but innovative new drugs are exempt, preserving profitability for novel therapies. Biosimilar adoption is lowering prices for existing drugs while expanding patient access and broadening the overall market. The expansion of telemedicine, which settled at a 15% utilization rate following the pandemic, is driving increased investment in healthcare IT. Looking at the long-term return outlook for healthcare ETFs, the expected annual return from 2025 to 2030 is 12–14% for VHT and 10–12% for XLV. Relative to the S&P 500, excess returns of 2–3 percentage points per year are anticipated, reflecting the sector's combination of defense and growth. With dividend reinvestment, total return potential of 15–17% is achievable.
Healthcare Sector Risks and Risk Management
Key risk factors in healthcare investing require careful monitoring. Regarding regulatory and drug pricing risk, Medicare drug price negotiations initially target 10 existing drugs, and any future expansion could weigh on pharmaceutical earnings. The Biden administration's drug pricing policies create margin pressure for pharmaceutical companies, while tighter FDA approval standards may increase the time and cost of drug development. Mitigation strategies include focusing on companies with innovative drug pipelines that benefit from regulatory exemptions, preferring companies with global market exposure to diversify U.S. pricing risk, and using diversified ETFs such as VHT and XLV to reduce company-specific risk. Regarding clinical trial failure risk, the success rate for pharmaceutical and biotech drug development is below 10%. Phase 3 clinical failures frequently trigger share price declines of 30% or more, and biotech companies with high pipeline dependency experience extreme volatility. Mitigation strategies include investing primarily in large-cap pharmaceutical companies that can spread risk across multiple pipeline assets, preferring companies with products already in the commercialization stage, and using ETFs rather than individual biotech stocks to achieve diversification. Regarding patent expiration risk, when a blockbuster drug loses patent protection, revenue can fall more than 80%; Merck's Keytruda faces patent expiration in 2028. Generic drug entry rapidly erodes market share, and companies approaching a patent cliff face share price pressure. Mitigation strategies include focusing on companies with rich drug pipelines that secure next-generation growth drivers, preferring companies that pursue label expansion strategies to extend effective patent life, and spreading patent expiration timelines across the portfolio. Regarding sector concentration risk, overweighting healthcare limits the benefits of diversification, exposes the portfolio to sector-specific regulatory and policy risks, and causes investors to miss rallies in other sectors. Mitigation strategies include capping healthcare exposure at 20–25% of the total portfolio, balancing across other sectors such as technology, financials, and consumer staples, using an asset allocation calculator to determine optimal sector weights, and using a rebalancing calculator to make quarterly adjustments. Regarding currency risk, U.S. healthcare ETFs are dollar-denominated assets, so Korean won weakness generates currency gains while won strength erodes returns. For example, a 12% healthcare ETF return combined with a -5% decline in the USD/KRW exchange rate results in a total return of only 7%. Mitigation strategies include setting the currency hedge ratio at 50% to reduce the impact of exchange rate fluctuations by half, relying on the mean-reversion tendency of exchange rates over long investment horizons, and increasing the hedge ratio to 80% when the USD/KRW rate falls below 1,250 won.
Conclusion
The healthcare sector's long-term growth outlook is bright, supported by the aging mega-trend and a favorable drug development pipeline. VHT offers higher growth potential through its inclusion of small- and mid-cap biotech names, while XLV provides superior stability with its large-cap concentration. Use a rebalancing calculator to manage healthcare sector exposure at a target weight of 20–25%, and use an asset allocation calculator to design an optimal allocation within a defensive portfolio.
Related Portfolios
#[KO] 리밸런싱 계산기#[KO] 자산배분 계산기#VHT#XLV#[KO] 헬스케어 ETF#[KO] 고령화
Related Articles
Have any questions?